<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>XALATAN - latanoprost solution </strong><br>Dispensing Solutions, Inc.<br></p></div>
<h1>Xalatan<span class="Sup">®</span><br>latanoprost ophthalmic solution<br>0.005% (50 µg/mL)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Latanoprost is a prostaglandin F<span class="Sub">2α</span> analogue. Its chemical name is isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate. Its molecular formula is C<span class="Sub">26</span>H<span class="Sub">40</span>O<span class="Sub">5</span> and its chemical structure is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f4881ec-2984-4853-bc25-5b14c3b79da7&amp;name=xalatan-01.jpg"></div>
<p>Latanoprost is a colorless to slightly yellow oil that is very soluble in acetonitrile and freely soluble in acetone, ethanol, ethyl acetate, isopropanol, methanol and octanol. It is practically insoluble in water.</p>
<p>XALATAN Sterile Ophthalmic Solution (latanoprost ophthalmic solution) is supplied as a sterile, isotonic, buffered aqueous solution of latanoprost with a pH of approximately 6.7 and an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 267 mOsmol/kg. Each mL of XALATAN contains 50 micrograms of latanoprost. Benzalkonium chloride, 0.02% is added as a preservative. The inactive ingredients are: sodium chloride, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous and water for injection. One drop contains approximately 1.5 µg of latanoprost.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> and visual field loss.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics/Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Latanoprost is absorbed through the cornea where the isopropyl ester prodrug is hydrolyzed to the acid form to become biologically active. Studies in man indicate that the peak concentration in the aqueous humor is reached about two hours after topical administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">The distribution volume in humans is 0.16 ± 0.02 L/kg. The acid of latanoprost can be measured in aqueous humor during the first 4 hours, and in plasma only during the first hour after local administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Latanoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to the biologically active acid. The active acid of latanoprost reaching the systemic circulation is primarily metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites via fatty acid β-oxidation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.4"></a><p></p>
<h3>Excretion</h3>
<p class="First">The elimination of the acid of latanoprost from human plasma is rapid (t<span class="Sub">1/2</span> =17 min) after both intravenous and topical administration. Systemic clearance is approximately 7 mL/min/kg. Following hepatic β-oxidation, the metabolites are mainly eliminated via the kidneys. Approximately 88% and 98% of the administered dose is recovered in the urine after topical and intravenous dosing, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-2.3"></a><p></p>
<h2>Animal Studies</h2>
<p class="First">In monkeys, latanoprost has been shown to induce increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris. The mechanism of increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> seems to be stimulation of melanin production in melanocytes of the iris, with no proliferative changes observed. The change in iris color may be permanent.</p>
<p>Ocular administration of latanoprost at a dose of 6 µg/eye/day (4 times the daily human dose) to cynomolgus monkeys has also been shown to induce increased palpebral fissure. This effect was reversible upon discontinuation of the drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">XALATAN Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">Patients with mean baseline intraocular pressure of 24 – 25 mmHg who were treated for 6 months in multi-center, randomized, controlled trials demonstrated 6 –8 mmHg reductions in intraocular pressure. This IOP reduction with XALATAN Sterile Ophthalmic Solution 0.005% dosed once daily was equivalent to the effect of timolol 0.5% dosed twice daily.</p>
<p>A 3-year open-label, prospective safety study with a 2-year extension phase was conducted to evaluate the progression of increased iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> with continuous use of XALATAN once-daily as adjunctive therapy in 519 patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. The analysis was based on observed-cases population of the 380 patients who continued in the extension phase.</p>
<p>Results showed that the onset of noticeable increased iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> occurred within the first year of treatment for the majority of the patients who developed noticeable increased iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>. Patients continued to show signs of increasing iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> throughout the five years of the study. Observation of increased iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> did not affect the incidence, nature or severity of adverse events (other than increased iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>) recorded in the study. IOP reduction was similar regardless of the development of increased iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> during the study.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to latanoprost, benzalkonium chloride or any other ingredients in this product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">XALATAN Sterile Ophthalmic Solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris, periorbital tissue (eyelid) and eyelashes, and <span class="product-label-link" type="condition" conceptid="4083923" conceptname="Growth of eyelashes">growth of eyelashes</span>. <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span> is expected to increase as long as XALATAN is administered. After discontinuation of XALATAN, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris is likely to be permanent while <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>. The effects of increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> beyond 5 years are not known.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">XALATAN Sterile Ophthalmic Solution may gradually increase the <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris. The eye color change is due to increased melanin content in the stromal  melanocytes of the iris rather than to an increase in the number of melanocytes. This change may not be noticeable for several months to years (see <span class="Bold"><a href="#Warnings">WARNINGS</a></span>). Typically, the brown <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with XALATAN can be continued in patients who develop noticeably increased iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, these patients should be examined regularly.</p>
<p>During clinical trials, the increase in brown iris pigment has not been shown to progress further upon discontinuation of treatment, but the resultant color change may be permanent.</p>
<p>Eyelid skin darkening, which may be reversible, has been reported in association with the use of XALATAN (see <span class="Bold"><a href="#Warnings">WARNINGS</a></span>).</p>
<p>XALATAN may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, the number of lashes or hairs, and misdirected <span class="product-label-link" type="condition" conceptid="4083923" conceptname="Growth of eyelashes">growth of eyelashes</span>. Eyelash changes are usually reversible upon discontinuation of treatment.</p>
<p>XALATAN should be used with caution in patients with a history of intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (<span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>/<span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>) and should generally not be used in patients with active intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span>, including <span class="product-label-link" type="condition" conceptid="4105178" conceptname="Cystoid macular edema">cystoid macular edema</span>, has been reported during treatment with XALATAN. These reports have mainly occurred in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>. XALATAN should be used with caution in patients who do not have an intact posterior capsule or who have known risk factors for <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>.</p>
<p>There is limited experience with XALATAN in the treatment of angle closure, inflammatory or <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">neovascular glaucoma</span>.</p>
<p>There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface (see <span class="Bold"><a href="#Information_For_Patients">PRECAUTIONS, Information for Patients</a></span>).</p>
<p>Contact lenses should be removed prior to the administration of XALATAN, and may be reinserted 15 minutes after administration (see <span class="Bold"><a href="#Information_For_Patients">PRECAUTIONS, Information for Patients</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Information_For_Patients"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">(see <span class="Bold"><a href="#Warnings">WARNINGS</a></span> and <span class="Bold"><a href="#Precautions">PRECAUTIONS</a></span>)</p>
<p>Patients should be advised about the potential for increased brown <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris, which may be permanent. Patients should also be informed about the possibility of eyelid skin darkening, which may be reversible after discontinuation of XALATAN.</p>
<p>Patients should also be informed of the possibility of eyelash and vellus hair changes in the treated eye during treatment with XALATAN. These changes may result in a disparity between eyes in length, thickness, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment.</p>
<p>Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated solutions.</p>
<p>Patients also should be advised that if they develop an intercurrent ocular condition (e.g., <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) or have ocular surgery, they should immediately seek their physician's advice concerning the continued use of the multiple-dose container.</p>
<p>Patients should be advised that if they develop any ocular reactions, particularly <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and lid reactions, they should immediately seek their physician's advice.</p>
<p>Patients should also be advised that XALATAN contains benzalkonium chloride, which may be absorbed by contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of XALATAN.</p>
<p>If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><span class="Italics">In vitro</span> studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with XALATAN. If such drugs are used they should be administered at least five (5) minutes apart.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Latanoprost was not mutagenic in bacteria, in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> or in mouse micronucleus tests.</p>
<p>Chromosome aberrations were observed <span class="Italics">in vitro</span> with human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.</p>
<p>Latanoprost was not carcinogenic in either mice or rats when administered by oral gavage at doses of up to 170 µg/kg/day (approximately 2,800 times the recommended maximum human dose) for up to 20 and 24 months, respectively.</p>
<p>Additional <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> studies on unscheduled DNA synthesis in rats were negative. Latanoprost has not been found to have any effect on male or female fertility in animal studies.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.5.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Reproduction studies have been performed in rats and rabbits. In rabbits an incidence of 4 of 16 dams had no viable fetuses at a dose that was approximately 80 times the maximum human dose, and the highest nonembryocidal dose in rabbits was approximately 15 times the maximum human dose. There are no adequate and well-controlled studies in pregnant women. XALATAN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when XALATAN is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Adverse events referred to in other sections of this insert</h2>
<p class="First">Eyelash changes (increased length, thickness, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, and number of lashes); eyelid skin darkening; intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (<span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>/<span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>); iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> changes; and <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>, including <span class="product-label-link" type="condition" conceptid="4105178" conceptname="Cystoid macular edema">cystoid macular edema</span> (see <span class="Bold"><a href="#Warnings">WARNINGS</a></span> and <span class="Bold"><a href="#Precautions">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Controlled Clinical Trials</h2>
<p class="First">The ocular adverse events and ocular signs and symptoms reported in 5 to 15% of the patients on XALATAN Sterile Ophthalmic Solution in the three 6-month, multi-center, double-masked, active-controlled trials were <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>, foreign body sensation, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris, and punctate epithelial <span class="product-label-link" type="condition" conceptid="436695" conceptname="Band-shaped keratopathy">keratopathy</span>.</p>
<p>Local <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span> was observed; however, less than 1% of the patients treated with XALATAN required discontinuation of therapy because of intolerance to <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>.</p>
<p>In addition to the above listed ocular events/signs and symptoms, the following were reported in 1 to 4% of the patients: <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, excessive tearing, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, lid crusting, lid <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, lid <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, lid <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>.</p>
<p>The following events were reported in less than 1% of the patients: <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span> and discharge from the eye.</p>
<p>During clinical studies, there were extremely rare reports of the following: retinal artery <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolus</span>, <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">retinal detachment</span>, and vitreous  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> from <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">diabetic retinopathy</span>.</p>
<p>The most common systemic adverse events seen with XALATAN were <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>/<span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>/flu, which occurred at a rate of approximately 4%. <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>/<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, muscle/joint/<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>/<span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reaction</span> each occurred at a rate of 1 to 2%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Clinical Practice</h2>
<p class="First">The following events have been identified during postmarketing use of XALATAN in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to XALATAN, or a combination of these factors, include: <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>; <span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">corneal edema</span> and erosions; <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>;  eyelash and vellus hair changes (increased length, thickness, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, and number); eyelid skin darkening; herpes <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>; intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (<span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>/<span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>); <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>; <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>, including <span class="product-label-link" type="condition" conceptid="4105178" conceptname="Cystoid macular edema">cystoid macular edema</span>; misdirected eyelashes sometimes resulting in <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Apart from ocular irritation and conjunctival or episcleral <span class="product-label-link" type="condition" conceptid="4146766" conceptname="Hyperemia">hyperemia</span>, the ocular effects of latanoprost administered at high doses are not known. Intravenous administration of large doses of latanoprost in monkeys has been associated with transient <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span>; however, in 11 patients with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> treated with latanoprost, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> was not induced. Intravenous infusion of up to 3 µg/kg in healthy volunteers produced mean plasma concentrations 200 times higher than during clinical treatment and no adverse reactions were observed. Intravenous dosages of 5.5 to 10 µg/kg caused <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
<p>If overdosage with XALATAN Sterile Ophthalmic Solution occurs, treatment should be symptomatic.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dosage is one drop (1.5 µg) in the affected eye(s) once daily in the evening.  If one dose is missed, treatment should continue with the next dose as normal. </p>
<p>The dosage of XALATAN Sterile Ophthalmic Solution should not exceed once daily; the combined use of two or more prostaglandins, or prostaglandin analogs including XALATAN Sterile Ophthalmic Solution is not recommended.  It has been shown that administration of these prostaglandin drug products more than once daily may decrease the intraocular pressure lowering effect or cause paradoxical elevations in IOP.</p>
<p>Reduction of the intraocular pressure starts approximately 3 to 4 hours after administration and the maximum effect is reached after 8 to 12 hours.</p>
<p>XALATAN may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">XALATAN Sterile Ophthalmic Solution is a clear, isotonic, buffered, preserved colorless solution of latanoprost 0.005% (50 µg/mL). It is supplied as a 2.5 mL solution in a 5 mL clear low density polyethylene bottle with a clear low density polyethylene dropper tip, a turquoise high density polyethylene screw cap, and a tamper-evident clear low density polyethylene overcap.</p>
<p><span class="Bold">2.5 mL fill, 0.005% (50 µg/mL)</span></p>
<p>    Package of 1 bottle      NDC 0013-8303-04</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Protect from light. Store unopened bottle(s) under refrigeration at 2° to 8°C (36° to 46°F). During shipment to the patient, the bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 8 days. Once a bottle is opened for use, it may be stored at room temperature up to 25°C (77°F) for 6 weeks.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f4881ec-2984-4853-bc25-5b14c3b79da7&amp;name=xalatan-02.jpg"></p>
<p>Manufactured By:<br>Catalent Pharma Solutions<br>Woodstock, IL 60098, USA</p>
<p>Pfizer Manufacturing Belgium NV<br>Puurs, Belgium</p>
<p>LAB-0135-9.0<br>May 2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 2.5 mL Sample Bottle Carton</h1>
<br><p class="First"><img alt="NDC 68258-8976-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f4881ec-2984-4853-bc25-5b14c3b79da7&amp;name=NDC%2068258-8976-02------PHARMACIA.jpg"></p>
<p>NDC 68258-8976-02<br></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Xalatan<span class="Sup">®</span><br>latanoprost ophthalmic solution</span></p>
<p>One 2.5 mL bottle<br>Sterile</p>
<p>0.005%<br>(125 µg/2.5 mL)</p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XALATAN 		
					</strong><br><span class="contentTableReg">latanoprost solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68258-8976(NDC:0013-8303)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>latanoprost</strong> (latanoprost) </td>
<td class="formItem">latanoprost</td>
<td class="formItem">50 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, dibasic anhydrous</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68258-8976-2</td>
<td class="formItem">2.5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020597</td>
<td class="formItem">03/20/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Dispensing Solutions, Inc.
							(066070785)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Dispensing Solutions, Inc.</td>
<td class="formItem"></td>
<td class="formItem">066070785</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>309e27fc-3503-4307-880c-2d9492423870</div>
<div>Set id: 0f4881ec-2984-4853-bc25-5b14c3b79da7</div>
<div>Version: 1</div>
<div>Effective Time: 20111006</div>
</div>
</div> <div class="DistributorName">Dispensing Solutions, Inc.</div></p>
</body></html>
